Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
To compared the efficacy and safety of rifampicin and rifabutin which included in the
standard treatment of anti-tuberculosis in HIV/AIDs patients combined with pulmonary
tuberculosis, a multi-center, prospective cohort will be established. Antiviral efficacy and
drug drug interaction will be investigated in order to provide optimized treatment for
HIV/AIDs with tuberculosis.
Phase:
N/A
Details
Lead Sponsor:
Shanghai Public Health Clinical Center
Collaborators:
Chongqing Public Health Medical Center Shenzhen Third People's Hospital The Fourth People's Hospital of Nanning The Fourth People’s Hospital of Nanning The Guangxi Zhuang Autonomous Region Longtan hospital Yunnan Provincial Infectious Disease Hospital Zhejiang University